1 40 1 Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1016/j.rmed.2004.04.007" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.rmed.2004.04.007</a> Rights Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s). Pages 708-720 Issue 8 Volume 98 Search for Full-text Locate full-text within NEOMED Library's e-journal collections <p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Gemifloxacin Once Daily For 7 Days Compared To Amoxicillin/clavulanic Acid Thrice Daily For 10 Days For The Treatment Of Community-acquired Pneumonia Of Suspected Pneumococcal Origin Publisher An entity responsible for making the resource available Respiratory Medicine Date A point or period of time associated with an event in the lifecycle of the resource 2004 2004-08 Subject The topic of the resource adults; antimicrobial resistance; Cardiovascular System & Cardiology; community-acquired pneumonia; fluoroquinolone; gemifloxacin; guidelines; levofloxacin; management; pneumococcal pneumonia; Respiratory System; streptococcus-pneumoniae; surveillance; therapy; trovafloxacin; united-states Creator An entity primarily responsible for making the resource Leophonte P; File T; Feldman C Description An account of the resource Context: Community-acquired pneumonia (CAP) is common among adults and contributes considerably to morbidity and mortality. Objective: To compare the safety and efficacy of gemifloxacin to high-dose amoxicillin/clavulanate for the treatment of CAP of suspected pneumococcal origin. Design: Randomized, multicentre, double-blind, double-dummy, parallel group Phase III study. Setting and participants: From September 1998 to July 1999, 324 patients with CAP were randomized at 102 centers in France, Poland and the Republic of South Africa. Intervention: Patients were double-blind randomized to receive either oral gemifloxacin 320 mg once daily for 7 days or oral amoxicillin/clavulanate 1 g/1 25 mg three times daily for 10 days. Main outcome measures: The main outcome measures were clinical, bacteriotogical, and radiological responses at the end of therapy (day 12-14) and follow-up (day 24-30) visits. Results: In 228 PP patients, clinical resolution at follow-up was 88.7% for 7-day gemifloxacin and 87.6% for 10-day amoxicillin/clavulanate [95% CI, -7.3, 9.5]. In 249 PP patients, clinical resolution at end of therapy was 95.3% for 7-day gemifloxacin vs. 90.1% for 10-day amoxicillin/clavutanate [95% Cl, -1.2, 11.7]. Bacteriologic response rates for the PP patients at end of therapy were 96.3% for 7-day gernifloxacin and 91.8% for the amoxicillin/clavulanate group [95% Cl, -4.7, 13.6]. Bacteriologic response rates at follow-up were 87.2% for 7-day gernifloxacin and 89.1% for the amoxicillin/clavulanate group [95% CI, -15.0, 11.2]. Specifically gernifloxacin eradicated 95.7% of Streptococcus pneumoniae including penicillin and macrolide resistant strains. Radiological response rates for the PP patients at end of therapy were 89.1% for 7-day gemifloxacin and 87.6% for the amoxicillin/clavulanate group. The most frequently reported drug-retated events were in the gernifloxacin group, diarrhea (6.0%) and rash (3.0%) and in the amoxicillin/clavulanate group, diarrhea (11.1%) and fungal infection, vaginitis and vomiting (each 2.0%). Overall there were statistically fewer withdrawals due to tack of therapeutic effect in the gemifloxacin group compared with the amoxicillin/clavulanate cohort, (95% Cl, -8.8;0.6; P = 0.03). Conclusion: Gemifloxacin 320 mg once daily for 7 days was found to be clinically, bacteriologically, and radiologically as effective as 10 days of amoxicillin/clavulanate 1 g/125 mg three times daily for the treatment of suspected pneumococcal CAR (C) 2004 Elsevier Ltd. All rights reserved. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1016/j.rmed.2004.04.007" target="_blank" rel="noreferrer noopener">10.1016/j.rmed.2004.04.007</a> Format The file format, physical medium, or dimensions of the resource Journal Article or Conference Abstract Publication 2004 adults Antimicrobial resistance Cardiovascular System & Cardiology Community-acquired pneumonia Feldman C File T Fluoroquinolone Gemifloxacin guidelines Journal Article or Conference Abstract Publication Leophonte P Levofloxacin Management pneumococcal pneumonia Respiratory Medicine Respiratory System streptococcus-pneumoniae surveillance therapy trovafloxacin united-states